全文获取类型
收费全文 | 2380篇 |
免费 | 168篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 112篇 |
妇产科学 | 118篇 |
基础医学 | 239篇 |
口腔科学 | 60篇 |
临床医学 | 247篇 |
内科学 | 420篇 |
皮肤病学 | 65篇 |
神经病学 | 106篇 |
特种医学 | 192篇 |
外科学 | 234篇 |
综合类 | 157篇 |
一般理论 | 1篇 |
预防医学 | 230篇 |
眼科学 | 35篇 |
药学 | 192篇 |
1篇 | |
中国医学 | 74篇 |
肿瘤学 | 67篇 |
出版年
2021年 | 28篇 |
2020年 | 23篇 |
2019年 | 17篇 |
2018年 | 24篇 |
2017年 | 29篇 |
2016年 | 35篇 |
2015年 | 47篇 |
2014年 | 65篇 |
2013年 | 80篇 |
2012年 | 102篇 |
2011年 | 87篇 |
2010年 | 83篇 |
2009年 | 64篇 |
2008年 | 86篇 |
2007年 | 62篇 |
2006年 | 57篇 |
2005年 | 52篇 |
2004年 | 46篇 |
2003年 | 49篇 |
2002年 | 42篇 |
2001年 | 55篇 |
2000年 | 45篇 |
1999年 | 35篇 |
1998年 | 51篇 |
1997年 | 68篇 |
1996年 | 57篇 |
1995年 | 48篇 |
1994年 | 58篇 |
1993年 | 44篇 |
1992年 | 31篇 |
1991年 | 30篇 |
1990年 | 30篇 |
1989年 | 46篇 |
1988年 | 53篇 |
1987年 | 41篇 |
1986年 | 34篇 |
1985年 | 32篇 |
1984年 | 20篇 |
1983年 | 20篇 |
1982年 | 17篇 |
1981年 | 32篇 |
1980年 | 20篇 |
1979年 | 26篇 |
1959年 | 35篇 |
1958年 | 58篇 |
1957年 | 87篇 |
1956年 | 45篇 |
1955年 | 76篇 |
1954年 | 67篇 |
1953年 | 17篇 |
排序方式: 共有2561条查询结果,搜索用时 15 毫秒
51.
52.
Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin 总被引:19,自引:2,他引:19
Extravasation of leukocytes into organized lymphoid tissues and into sites of inflammation is critical to immune surveillance. Leukocyte migration to peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN) and Peyer's patches (PP) depends on L-selectin, which recognizes carbohydrate-bearing, sialomucin-like endothelial cell surface glycoproteins. Two of these ligands have been identified at the molecular level. One is the potentially soluble mucin, GlyCAM 1, which is almost exclusively produced by high endothelial venules (HEV) of PLN and MLN. The second HEV ligand for L-selectin is the membrane-bound sialomucin CD34. Historically, this molecule has been successfully used to purify human pluripotent bone marrow stem cells, and limited data suggest that human CD34 is present on the vascular endothelium of several organs. Here we describe a comprehensive analysis of the vascular expression of CD34 in murine tissues using a highly specific antimurine CD34 polyclonal antibody. CD34 was detected on vessels in all organs examined and was expressed during pancreatic and skin inflammatory episodes. A subset of HEV-like vessels in the inflamed pancreas of nonobese diabetic (NOD) mice are positive for both CD34 and GlyCAM 1, and bind to an L-selectin/immunoglobulin G (IgG) chimeric probe. Finally, we found that CD34 is present on vessels of deafferentiated PLN, despite the fact that these vessels are no longer able to interact with L-selectin or support lymphocyte binding in vitro or trafficking in vivo. Our data suggest that the regulation of posttranslational carbohydrate modifications of CD34 is critical in determining its capability to act as an L-selectin ligand. Based on its ubiquitous expression, we propose that an appropriately glycosylated form of vascular CD34 may act as a ligand for L-selectin-mediated leukocyte trafficking to both lymphoid and nonlymphoid sites. 相似文献
53.
54.
55.
The widespread assumption that cytoplasts generated from human polymorphonuclear leukocytes (PMNs) are vesicles consisting solely of cytoplasm surrounded by plasma membrane and devoid of granule activity remains to be tested. PMN cytoplasts were prepared by centrifugation of intact cells on a Ficoll step gradient in the presence of cytochalasin B. Two granule membrane markers, Mol, a fluorometrically detectable antigen, and cytochrome b, both of which have been shown to translocate to the plasma membrane during granule release, were compared for their activity in cytoplasts and intact PMNs. We found that the amount of Mol detected on the plasma membrane of intact PMNs, as compared with other membrane markers (such as antigens LFA-1 and beta 2m), increased 1.6- fold upon exposure of PMNs to Ficoll plus cytochalasin B prior to centrifugation. Another twofold increase in Mol expression occurred upon cytoplast preparation. Release of the granule enzymes, vitamin B12- binding protein, and lysozyme were also followed and correlated well (r = .78 and .92) with the amount of Mol antigen present on the cell surface. Cytochrome b was also found to be higher (1.4-fold) on plasma membranes isolated from cytoplasts than on plasma membranes isolated from intact control cells. These results indicate that some fusion of granule membranes and plasma membranes occurred during treatment of PMNs with Ficoll plus cytochalasin b and during cytoplast preparation. 相似文献
56.
57.
Styles LA; Schalkwijk CG; Aarsman AJ; Vichinsky EP; Lubin BH; Kuypers FA 《Blood》1996,87(6):2573-2578
Acute chest syndrome (ACS) is associated with significant morbidity and is the leading cause of death in patients with sickle cell disease (SCD). Recent reports suggest that bone marrow fat embolism can be detected in many cases of severe ACS. Secretory phospholipase A2 (sPLA2) is an important inflammatory mediator and liberates free fatty acids, which are felt to be responsible for the acute lung injury of the fat embolism syndrome. We measured SPLA2 levels in 35 SCD patients during 20 admissions for ACS, 10 admissions for vaso-occlusive crisis, and during 12 clinic visits when patients were at the steady state. Eleven non-SCD patients with pneumonia were also evaluated. To determine if there was a relationship between sPLA2 and the severity of ACS we correlated SPLA2 levels with the clinical course of the patient. In comparison with normal controls (mean = 3.1 +/- 1.1 ng/mL), the non- SCD patients with pneumonia (mean = 68.6 +/- 82.9 ng/mL) and all three SCD patient groups had an elevation of SPLA2 (steady state mean = 10.0 +/- 8.4 ng/mL; vaso-occlusive crisis mean = 23.7 +/- 40.5 ng/mL; ACS mean = 336 +/- 209 ng/mL). In patients with ACS sPLA2 levels were 100- fold greater than normal control values, 35 times greater than values in SCD patients at baseline, and five times greater than non-SCD patients with pneumonia. The degree of SPLA2 elevation in ACS correlated with three different measures of clinical severity and, in patients followed sequentially, the rise in SPLA2 coincided with the onset of ACS. The dramatic elevation of SPLA2 in patients with ACS but not in patients with vaso-occlusive crisis or non-SCD patients with pneumonia and the correlation between levels of SPLA2 and clinical severity suggest a role for SPLA2 in the diagnosis and, perhaps, in the pathophysiology of patients with ACS. 相似文献
58.
The relationship between parent feeding styles and general parenting with loss of control eating in treatment‐seeking overweight and obese children 下载免费PDF全文
59.
Andrea LA?TOVKOVá Pavlina KLUSá?KOVá Zdenka FENCLOVá Vincent BONNETERRE Daniela PELCLOVá 《Industrial health》2015,53(6):562-568
The objective of this study is to describe a case-series of potassium aluminium
tetrafluoride (KAlF4)-induced occupational asthma (OA) and/or occupational
rhinitis (OR). The study involves five patients from a heat-exchanger production line who
were examined (including specific inhalation challenge tests) for suspected OA and/or OR
caused by a flux containing almost 100% KAlF4 − with fluorides’ workplace air
concentrations ranging between 1.7 and 2.8 mg/m3. No subject had a previous
history of asthma. All five patients had a positive specific challenge test (three
patients were diagnosed with OA alone, one with OR and one with both OR and OA). At the
follow-up visit, after three years on average, all patients needed permanent
corticosteroid therapy (four topical, one oral). After elimination from the exposure, only
one of the observed subjects gave an indication of an improvement, two subjects stabilized
and two worsened. Our case series focuses on the correlation between patients’ exposure to
fluorides in air-conditioner production and the subsequent occurrence of OR/OA. Currently,
it is uncertain whether these OR/OA were caused by hypersensitivity or irritation. 相似文献
60.
Fiona G. Kouyoumdjian Kathryn E. McIsaac Jessica Liauw Samantha Green Fareen Karachiwalla Winnie Siu Kaite Burkholder Ingrid Binswanger Lori Kiefer Stuart A. Kinner Mo Korchinski Flora I. Matheson Pam Young Stephen W. Hwang 《American journal of public health》2015,105(4):e13-e33
We systematically reviewed randomized controlled trials of interventions to improve the health of people during imprisonment or in the year after release. We searched 14 biomedical and social science databases in 2014, and identified 95 studies.Most studies involved only men or a majority of men (70/83 studies in which gender was specified); only 16 studies focused on adolescents. Most studies were conducted in the United States (n = 57). The risk of bias for outcomes in almost all studies was unclear or high (n = 91). In 59 studies, interventions led to improved mental health, substance use, infectious diseases, or health service utilization outcomes; in 42 of these studies, outcomes were measured in the community after release.Improving the health of people who experience imprisonment requires knowledge generation and knowledge translation, including implementation of effective interventions.Worldwide, more than 11 million people are imprisoned at any given time, and the prison population continues to grow at a rate faster than that of the general population.1 Substantial evidence reveals that people who have experienced imprisonment have poor health compared with the general population, as indicated by the prevalence of mental illness, infectious diseases, chronic diseases, and mortality.2There are several reasons to focus on improving the health of people who experience imprisonment.3 The burden of disease in this population affects the general population directly through increased health care costs and through the transmission of communicable diseases (e.g., HIV, HCV, and tuberculosis) after people are released from detention. Imprisonment has also been associated with worse health in family members of those who are detained, compared with the general population, including chronic diseases4 and poor mental health5,6 in adult relatives and mortality in male children.7 At the community level, higher rates of incarceration have been associated with adverse health outcomes, such as sexually transmitted infections and teen pregnancies.8 There is also evidence that poor health in persons who are released from detention, particularly those with inadequately treated mental illness and substance use disorders,3 may affect public safety and reincarceration rates,3 and that better access to health care is associated with less recidivism.9,10 Finally, the right to health and health care is enshrined in international human rights documents,11,12 and is a legislated responsibility of governments in many countries.Intervening during imprisonment and at the time of release could improve the health of people who experience imprisonment and public health overall.13 Knowledge translation efforts, such as syntheses of effective interventions, could lead to the implementation and further evaluation of interventions,14 and identify areas where further research is needed. To date, only syntheses with a limited focus have been conducted in this population, for example, reviews of interventions related to HIV15 or for persons with serious mental illness.16 Decision makers, practitioners, and researchers in this field would benefit from a broader understanding of the state of evidence regarding interventions to improve health in people who experience imprisonment.To address this gap, we systematically reviewed randomized controlled trials of interventions to improve health in persons during imprisonment and in the year after release. We chose this population because we view imprisonment as a unique opportunity to deliver and to link with interventions for this population, and to highlight interventions that could be implemented by those responsible for the administration of correctional facilities. We limited this study to randomized controlled trials, recognizing that randomized controlled trials provide the highest quality of evidence compared with other study designs.17 相似文献